Efficacy of rituximab combined with cyclophosphamide and fludarabine in treatment of chronic lymphocytic leukemia: a Meta-analysis
10.3760/cma.j.issn.1009-9921.2019.09.007
- VernacularTitle: 利妥昔单抗联合环磷酰胺与氟达拉滨治疗慢性淋巴细胞白血病效果的Meta分析
- Author:
Feifei LIU
1
;
Jinlong HUANG
2
;
Yang LIU
1
;
Yan WANG
1
;
Guilan LAI
1
;
Jianzhen SHEN
1
Author Information
1. Department of Hematology, Fujian Medical Universal Union Hospital, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Blood Medicine Center, Fuzhou 350001, China
2. Department of Rheumatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350001, China
- Publication Type:Journal Article
- Keywords:
Leukemia, lymphoid;
Cyclophosphamide;
Rituximab;
Fludarabine;
Meta-analysis
- From:
Journal of Leukemia & Lymphoma
2019;28(9):541-545
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical efficacy and safety of fludarabine combined with cyclophosphamide (FC) and fludarabine and cyclophosphamide combined with rituximab (FCR) in the treatment of chronic lymphocytic leukemia (CLL).
Methods:FCR regimen was selected as the experimental group, and FC regimen was selected as the control group. The studies were retrieved from PubMed, Cochrane Library, Embase, CNKI, Wangfang and VIP databases by computer and the references listed in these studies were further searched. The randomized controlled trials (RCT) meeting inclusive criteria were extracted, and the quality was evaluated and cross-checked independently according to Cochrane Handbook for Systematic Reviews of Interventions, and then the Meta-analysis was conducted by using StataMP 14.0 software.
Results:A total of 7 studies and 1 985 patients were included. The complete remission rate and overall response rate of FCR regimen were better than those of FC regimen, and the differences were statistically significant (RR = 1.89, 95% CI 1.64-2.18, P < 0.01; RR = 1.15, 95% CI 1.10-1.21, P < 0.01). In terms of grade Ⅲ-Ⅳ adverse reactions, the neutropenia of FCR regimen was more severe than that of FC regimen, and the difference was statistically significant (RR = 1.25, 95% CI 1.01-1.55, P = 0.004).
Conclusion:The FCR regimen has a better clinical outcome and prognosis than the FC regimen, and is accompanied by more severe grade Ⅲ-Ⅳ neutropenia.
